DeepMed Research

DR. REDDY'S LABORATORIES LIMITED

🇱🇰Sri Lanka

Country: 🇱🇰Sri Lanka

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Rituxan
Biological: DRL_RI
Biological: MabThera

First Posted Date: 2014-11-20

Last Posted Date: 2020-01-13

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 276

Registration Number: NCT02296775

Locations: 🇮🇳
Maulana Azad Medical College & Associated Lok Nayak Hospitals, New Delhi, Delhi, India
🇮🇳
lndraprastha Apollo Hospitals, New Delhi, Delhi, India
🇮🇳
Sushruta Multispeciality Hospital & Research Centre Pvt. Ltd, Hubli, Karnataka, India

and more 25 locations

Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Amlodipine besylate/Atorvastatin calcium

First Posted Date: 2014-11-19

Last Posted Date: 2014-11-19

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 80

Registration Number: NCT02295046

Locations: 🇩🇪
3S-Pharmacological Consultation & Research GmbH, D-27243 Harpstedt, Koenigsberger, Germany

Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Amlodipine besylate/Atorvastatin calcium

First Posted Date: 2014-11-17

Last Posted Date: 2014-11-17

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 90

Registration Number: NCT02292069

Locations: 🇮🇳
Veeda Clinical Research Pvt Ltd, Ahmedabad, Gujrat, India

Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cymbalta®
Drug: Duloxetine

First Posted Date: 2014-11-14

Last Posted Date: 2014-11-14

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 76

Registration Number: NCT02291341

Locations: 🇮🇳
BA Research India Ltd, Ahmedabad, Gujrat, India

Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cymbalta®
Drug: Duloxetine

First Posted Date: 2014-11-14

Last Posted Date: 2014-11-14

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 76

Registration Number: NCT02291367

Locations: 🇮🇳
BA Research India Ltd, Ahmedabad, Gujrat, India

DFN-02 Open Label Safety Study in Patients With Acute Migraine

Phase 3

Completed

Conditions: Acute Migraine

Interventions: Drug: DFN-02

First Posted Date: 2014-10-30

Last Posted Date: 2018-03-09

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 167

Registration Number: NCT02279082

Locations: 🇺🇸
California Medical Clinic for Headache, Santa Monica, California, United States
🇺🇸
Clinvest/A Division of Banyan Group, Inc., Springfield, Missouri, United States
🇺🇸
Arizona Research Center, Phoenix, Arizona, United States

and more 21 locations

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Phase 1

Completed

Conditions: Ovarian Epithelial Cancer Recurrent

Interventions: Drug: Doxorubicin Hydrochloride Liposome Injection

First Posted Date: 2014-10-09

Last Posted Date: 2016-09-23

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 49

Registration Number: NCT02260544

Locations: 🇮🇳
Dr. G. Viswanathan Speciality Hospitals, Trichy, Tamil Nadu, India
🇮🇳
Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
🇮🇳
City Cancer Center, Vijaywada, Andhra Pradesh, India

and more 8 locations

A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers

Phase 1

Conditions: Pharmacokinetics

Interventions: Biological: DRL_PG
Biological: Pegfilgrastim Form A
Biological: Pegfilgrastim Form B

First Posted Date: 2014-07-31

Last Posted Date: 2014-07-31

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 192

Registration Number: NCT02205320

Locations: 🇺🇸
QPS Bio-Kinetic, Springfield, Missouri, United States

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: XP23829 400 mg QD
Drug: XP 23829 800 mg QD
Drug: XP23829 400 mg BID
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2022-04-12

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 200

Registration Number: NCT02173301

Locations: 🇺🇸
XenoPort Investigational Site, West Jordan, Utah, United States

Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Phase 2

Completed

Conditions: Head Lice Infestation

Interventions: Drug: Abametapir Lotion 0.74% w/w
Drug: Vehicle Lotion

First Posted Date: 2014-03-27

Last Posted Date: 2021-05-11

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 50

Registration Number: NCT02097485

Locations: 🇦🇺
National Head Lice Treatment Centre, Ringwood East, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy